Mass tort settlements work by consolidating thousands of individual lawsuits over the same product or event into a single federal court, testing a sample of cases before juries, and then negotiating a master agreement that pays each claimant based on their own injuries and evidence. Every plaintiff keeps a separate case and a separate payout, which is what makes a mass tort different from a class action and what makes the money take years to arrive.
The rest of the mechanics, from the panel of judges that orders consolidation to the trust that holds the money before checks go out, follow a fairly consistent pattern across cases as varied as opioids, Roundup, military earplugs, and PFAS water contamination.
From Lawsuit to Settlement
Most mass tort litigation moves through the same sequence: consolidation, leadership appointments, discovery, bellwether trials, and a negotiated master agreement. The arc can stretch a decade.
Consolidation in Multidistrict Litigation
When similar lawsuits are filed across the country, the Judicial Panel on Multidistrict Litigation, a body of seven federal judges appointed by the Chief Justice, can transfer all of them to a single federal court for coordinated pretrial proceedings. Congress created this mechanism in 1968 under 28 U.S.C. ยง 1407, and it is known as multidistrict litigation, or MDL. One judge handles discovery, motions, and case management for every consolidated case, which eliminates the duplication that would happen if hundreds of courts ran identical disputes in parallel.
MDLs now dominate federal civil dockets. By 2018 they accounted for more than half of all pending federal civil cases, and as of late 2022 there were nearly 400,000 individual cases pending across active MDLs.
Consolidation is only for pretrial purposes. Under the Supreme Court’s ruling in Lexecon Inc. v. Milberg Weiss (1998), cases must be sent back to their original courts for trial if they do not settle. Each lawsuit also keeps its individual legal identity throughout the process, which matters when the money is eventually divided.
Leadership and Discovery
Once an MDL is established, the presiding judge appoints a leadership structure. On the plaintiff side, that typically includes lead counsel and a steering committee responsible for strategy, expert preparation, and managing the document volume. The defense side gets a comparable structure. The judge also enters case management orders and discovery schedules that govern every consolidated claim.
Discovery can last years. It involves depositions, expert reports, interrogatories, and the production of corporate documents that may number in the millions of pages. Both sides use it to build the factual record that will drive either trial outcomes or a settlement.
Bellwether Trials
Before a global settlement can be negotiated, both sides need a sense of what juries think the claims are worth. That is what bellwether trials are for. A small number of cases go to trial as a representative sample of the broader litigation, and the results give plaintiffs and defendants a benchmark for valuing the remaining claims.
Bellwethers can be structured in different ways. Some courts bifurcate them, separating liability from damages. Some let plaintiffs volunteer; others pick cases to ensure a cross-section of injury types and severity. The verdicts are almost always non-binding on the remaining cases, so any individual plaintiff can still insist on their own trial. In practice, bellwether outcomes heavily shape the terms of whatever global deal follows.
The Master Settlement Agreement
MDL judges often appoint settlement masters or special masters, typically retired judges or experienced attorneys, to facilitate negotiations. These neutrals schedule meetings, mediate disputes, and sometimes coordinate with parallel state-court cases to bring all parties to the table.
When the parties reach a deal, they execute a Master Settlement Agreement that spells out how claims will be registered, how eligibility will be determined, and how payments will be calculated. These agreements almost always include a “walk-away clause” that lets the defendant back out if fewer than a specified percentage of plaintiffs, often around 85%, agree to participate. If enrollment falls short, the deal can collapse and the litigation restarts.
Why This Is Not a Class Action
The two structures are often confused, and the difference matters for anyone deciding whether to file a claim. In a class action, a court certifies a group of plaintiffs as a single “class” represented by one or a few lead plaintiffs. Everyone in the class is treated identically unless they affirmatively opt out. Settlements are typically divided equally or proportionally among all class members.
In a mass tort, every plaintiff is an individual. Each must prove their own injuries, their own exposure to the product or substance, and their own damages. There is no class certification. Cases are consolidated for efficiency, but compensation is tailored to each person’s circumstances. Someone with a terminal cancer diagnosis will receive far more than someone with a minor injury, even if both were harmed by the same product.
The trade-off is time and cost. Class actions are faster and cheaper per person but give individuals less control and often result in smaller per-person payouts. Mass torts offer personalized outcomes but involve longer timelines and higher litigation expenses.
How Individual Payouts Are Calculated
Once a global settlement fund is established, the money does not get split evenly. A court-appointed administrator or allocation neutral reviews each claim and assigns compensation using a structured set of criteria.
The main factors are:
- Injury severity. Claims involving permanent disabilities, life-threatening illnesses, or death receive the highest payouts. A plaintiff with mild, temporary symptoms might receive a few thousand dollars, while someone with severe injuries could receive many times that amount.
- Economic losses. Documented medical bills, surgeries, rehabilitation, lost wages, and future treatment costs are calculated first as the measurable foundation of the claim.
- Non-economic damages. Pain and suffering, emotional distress, and loss of quality of life are factored on top of economic losses.
- Strength of evidence. Medical records, expert testimony, and proof linking the injury directly to the defendant’s product are critical. Incomplete documentation or a weak causal link reduces the payout.
Many settlements translate these factors into dollars through a points-based matrix. The matrix assigns numerical scores based on the specific diagnosis, the claimant’s age, and comorbidities such as smoking history or obesity. Each point carries an agreed dollar value, so higher totals yield higher awards. In some cases, a third-party allocation neutral designs and administers the matrix to reduce conflicts of interest among the plaintiffs’ attorneys who negotiated the deal.
The Roundup deal announced by Bayer on February 17, 2026 illustrates the range. Individual payouts under that $7.25 billion national class settlement are projected between $6,000 and $165,000, with the highest amounts reserved for professional users diagnosed with aggressive non-Hodgkin lymphoma before age 60. Payments would be spread over up to 21 years.
What Comes Out Before the Check
The gross award is not what a claimant receives. Several deductions come off the top.
Attorney fees in mass torts are typically contingency-based, ranging from 25% to 40% of the individual recovery. Case expenses, including expert witness fees and medical record retrieval, are also deducted from the settlement funds. And because Medicare, Medicaid, and other government programs may have paid for the claimant’s medical treatment, those programs assert liens that must be negotiated and satisfied before final distribution.
By one estimate, only about 53 cents of every tort dollar ultimately reaches the claimant, with the remainder going to litigation costs, administrative expenses, and attorney fees.
Taxes are a separate layer. Under IRC Section 104(a)(2), damages received on account of personal physical injuries or physical sickness are excluded from gross income. That applies to both lump-sum and structured periodic payments, and it extends to lost wages that stem from a physical injury. Damages for non-physical injuries, such as emotional distress or humiliation, are generally taxable unless they reimburse actual medical expenses that were not previously deducted. Punitive damages are almost always taxable.
How the settlement agreement characterizes the payments matters. If the agreement is silent on allocation, the IRS determines taxability based on the payor’s intent, and courts may treat the entire amount as taxable income. Claimants bear the burden of proving how a lump-sum settlement should be allocated among damage categories. Attorney fees add a complication: under the Supreme Court’s ruling in Commissioner v. Banks (2005), plaintiffs are often taxable on the portion of a settlement that covers their lawyers’ fees, and recent legislation has made it permanently impossible to deduct those fees as miscellaneous itemized deductions.
Timeline and How the Money Is Held
From the initial filing of lawsuits to the distribution of settlement checks, mass tort cases typically take two to four years to resolve. Once a global settlement is approved, the individual allocation phase alone generally requires six to twelve months. Larger settlements pay out over much longer horizons: Purdue Pharma and Sackler family payments run through 2029, and the National Opioid Settlement distributor payments are spread over 18 years.
Settlement funds are usually held in a Qualified Settlement Fund, a temporary trust established under IRC Section 468B that acts as a holding vehicle while claims are processed. The QSF structure offers tax advantages: defendants get an immediate tax deduction when they deposit money into the fund, and plaintiffs are generally not taxed until the money is actually distributed to them. The QSF also provides time to negotiate government liens and to set up special needs trusts for plaintiffs who need to preserve eligibility for public benefits.
A claims administrator, often a specialized firm appointed by the court, takes over logistics after approval. The administrator verifies eligibility, reviews documentation, applies the settlement’s allocation protocol, and issues payments. Where a settlement uses a first-in, first-out order, early filers get paid first; the 3M Combat Arms earplug settlement, for example, had paid out over $3.1 billion to more than 231,000 claimants by January 2026, with deferred and extraordinary injury payments continuing through 2029.
What Active Settlements Look Like
Several of the largest mass tort settlements in history are currently paying claimants, and each shows a different piece of the machinery in operation.
Opioids
The Purdue Pharma and Sackler family settlement became legally effective on May 1, 2026, with initial disbursements of over $2.4 billion. The Sackler family is permanently barred from selling opioids in the United States and must make public more than 30 million documents related to their opioid business. Purdue’s manufacturing operations transferred to a new entity called Knoa Pharma LLC, which is prohibited from marketing opioids and is overseen by an independent monitor. Remaining Sackler payments of roughly $500 million per year are scheduled through 2029, with total funding for addiction treatment spanning 15 years.
Under the broader National Opioid Settlement, at least 70% of funds must go toward opioid remediation. Advocacy groups have noted that families and individual victims have received less than 2% of the settlement money, with the vast majority directed to government entities for public health responses. The opioid resolutions are a reminder that not every mass settlement pays individuals; some pay governments.
3M Combat Arms Earplugs
The $6 billion earplug settlement covers approximately 250,000 to 271,000 claims by service members and veterans alleging hearing damage. Payments are processed on a first-in, first-out basis. The federal MDL has been wound down, with all cases dismissed following settlement or notice. A dispute in March 2026 saw a Special Master invalidate hundreds of claims submitted on behalf of Ugandan clients after verification failures by the responsible law firm, which shows how strictly administrators police the documentation requirements.
Roundup
Bayer’s $7.25 billion national class settlement, announced in February 2026 and preliminarily approved by a Missouri state court judge in March 2026, is intended to resolve tens of thousands of pending claims. It follows an earlier $11 billion settlement in 2020 that resolved roughly 100,000 lawsuits. Approximately 60,000 active cases remained as of March 2026. The U.S. Supreme Court is separately considering Monsanto Co. v. Durnell, which could determine whether federal labeling law preempts state failure-to-warn claims and reshape the litigation.
Johnson & Johnson Talcum Powder
After three failed attempts to resolve talc claims through subsidiary bankruptcies, Johnson & Johnson is litigating more than 67,000 pending cases in the MDL. A bankruptcy judge rejected the company’s most recent $8 to $9 billion plan in March 2025, finding that J&J lacked the financial distress to justify the bankruptcy approach. Bloomberg Intelligence analysts have estimated a final resolution could reach $11 billion. Recent jury verdicts have been substantial: a Baltimore jury awarded $1.5 billion to a single mesothelioma victim in December 2025, though a separate California verdict of $966 million was later reduced to $16 million after a judge struck the punitive damages.
Camp Lejeune
Claims stemming from toxic water contamination at the Marine Corps base are advancing under the Camp Lejeune Justice Act, part of the 2022 PACT Act. As of February 2026, 408,860 administrative claims had been filed with the Navy. The Department of Justice’s “elective option” offers between $100,000 and $550,000 based on injury type and exposure duration. Of 2,353 approved settlement offers worth a combined $691.3 million, 1,554 had been accepted. About two dozen cases are slated for potential bellwether trials later in 2026.
PFAS Water Contamination
The combined 3M and DuPont-related settlements offer up to $14 billion for public water systems affected by PFAS contamination. All four settlement agreements, covering 3M, DuPont-related entities, Tyco, and BASF, have received final approval from the MDL judge in the District of South Carolina. Phase 2 claim deadlines for water systems that have not yet detected PFAS or did so recently run through mid-2026. Systems that miss testing and filing deadlines forfeit both their settlement funds and their right to sue. Personal injury claims related to PFAS exposure remain a separate, unresolved area.
Social Media and GLP-1 Drugs
Two large MDLs are still in the pretrial phase and have no global settlement. The social media addiction MDL in the Northern District of California contained over 2,500 pending cases as of mid-2026, with roughly 1,000 more in California state court, and defendants include Meta, Google, TikTok, and Snap. A Los Angeles jury found Meta and YouTube liable for negligent design and awarded $6 million in a March 2026 bellwether. TikTok and Snap reached confidential settlements in January 2026 shortly before jury selection in a California bellwether.
The GLP-1 gastrointestinal injury MDL (MDL 3094) in the Eastern District of Pennsylvania had 3,763 pending cases as of June 2026, with a separate vision-loss MDL also established. Plaintiffs allege severe gastroparesis, intestinal obstruction, and permanent vision loss from a condition called NAION. No settlements or bellwether trials have occurred, and the litigation remains in expert discovery.
Both illustrate the front end of the process this article describes: consolidation is complete, bellwethers are on the horizon, and any master settlement is still years away.